Veradermics $294.8M IPO to Fund Phase III Hair Loss Trials

Veradermics has raised approximately $294.8 million through its initial public offering (IPO). 

The New Haven, Connecticut-based company sold 17,339,294 shares of common stock at $17.00 per share in its upsized offering. Shares began trading on the New York Stock Exchange on February 4, 2026, under the ticker symbol MANE.

Veradermics is a dermatologist-founded biopharma that develops treatments for aesthetic and dermatological conditions. Its main focus is pattern hair loss, also known as androgenetic alopecia, a condition that causes progressive thinning of scalp hair. 

Current treatment options remain limited, with a slow onset of hair growth, inconsistent results and tolerability concerns.

Veradermics’ lead investigational therapy, VDPHL01, is an extended-release oral formulation of minoxidil being developed for pattern hair loss in both men and women. Minoxidil was originally developed as a blood pressure drug but was later observed to stimulate hair growth.

The formulation is designed to maintain drug levels associated with hair growth while avoiding spikes linked to cardiovascular side effects.

VDPHL01 uses a proprietary extended-release gel matrix tablet designed to deliver steady exposure of minoxidil over time. This release profile aims to maintain drug concentrations above the “hair growth threshold” while remaining below levels associated with cardiac activity.

Veradermics is evaluating VDPHL01 in three randomized, double-blind, placebo-controlled trials intended to support a future FDA submission. These include two trials in men and one trial in women with mild-to-moderate pattern hair loss.

The first study, a Phase II/III trial enrolling 519 male participants, is evaluating two dosing regimens of the therapy over 52 weeks of treatment. The co-primary endpoints measure change in non-vellus hair count per square centimeter and patient-reported improvement in hair coverage after 24 weeks. Non-vellus hairs are thicker, visible scalp hairs.

A confirmatory Phase III trial in men is designed to enroll approximately 498 patients with mild-to-moderate hair loss, while a Phase II/III trial in women is designed to enroll about 552 participants.

The company recently completed enrollment in the second pivotal Phase III trial evaluating VDPHL01 in men with pattern hair loss. The randomized, double-blind, placebo-controlled study enrolled 536 participants and is assessing two dosing regimens over 52 weeks.

Across the company’s male Phase III program, more than 1,000 participants have been enrolled. Topline results from the first trial are expected in the first half of 2026, while data from the confirmatory study are anticipated in the second half of the year.

In a Phase I study, the extended-release formulation delivered nearly twice the total exposure to minoxidil over 12 hours compared with a 2.5 mg immediate-release formulation while maintaining peak concentrations below cardiac thresholds.

Preliminary findings from an exploratory Phase II trial in patients with mild-to-moderate pattern hair loss also suggested measurable hair growth after four months of treatment in a small male cohort, supporting continued evaluation in later-stage trials.

Existing FDA-approved therapies include oral finasteride for men and topical minoxidil for both sexes. However, topical treatments often see high discontinuation rates, with about 86% of users stopping within a year.

Immediate-release oral minoxidil is sometimes prescribed off-label for hair loss. But the formulation can produce rapid concentration spikes associated with cardiovascular effects.

The extended-release formulation used in VDPHL01 is intended to maintain drug concentrations above the minimum level associated with hair growth — approximately 1.62 ng/mL — while remaining below concentrations associated with cardiac effects, which occur at roughly 20 ng/mL.

If approved, the therapy would be developed as a non-hormonal oral treatment for pattern hair loss in both men and women. Currently, there are no FDA-approved oral therapies for pattern hair loss in women.

Veradermics is pursuing approval through the FDA’s 505(b)(2) pathway, which allows sponsors to rely partly on existing safety and efficacy data from previously approved drugs.

Other companies are also pursuing new approaches for androgenetic alopecia. Pelage Pharmaceuticals raised $120 million in Series B financing in 2025 to advance PP405, a topical small molecule designed to reactivate dormant hair follicle stem cells and restart hair growth. Early results from a Phase II trial suggested the therapy was well tolerated, and the company plans to begin Phase III trials in 2026.

If you want your company to be featured on Xtalks.com, please email [email protected].